Novo retains only a fraction of its drugs’ list prices, with the rest paid to companies that manage pharmacy benefits for insurers and employers, CEO Jorgensen said. — Bloomberg
NEW YORK: Novo Nordisk A/S chief executive officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy before a congressional committee led by Senator Bernie Sanders – it’s middlemen.
Novo retains only a fraction of its drugs’ list prices, with the rest paid to companies that manage pharmacy benefits for insurers and employers, according to Jorgensen’s written testimony that was viewed by Bloomberg ahead of a hearing in Washington.
